Novartis India Limited (BOM:500672)
India · Delayed Price · Currency is INR | Market Cap | 20.51B -8.2% |
| Revenue (ttm) | 3.48B -1.7% |
| Net Income | 972.30M +12.7% |
| EPS | 39.38 +12.7% |
| Shares Out | 24.69M |
| PE Ratio | 21.10 |
| Forward PE | n/a |
| Dividend | 25.00 (3.01%) |
| Ex-Dividend Date | Jul 23, 2025 |
| Volume | 5,778 |
| Average Volume | 10,451 |
| Open | 825.00 |
| Previous Close | 830.40 |
| Day's Range | 821.10 - 837.75 |
| 52-Week Range | 744.95 - 1,099.90 |
| Beta | -0.06 |
| RSI | 61.51 |
| Earnings Date | Jan 28, 2026 |
About Novartis India
Novartis India Limited is involved in the pharmaceutical business in India. The company offers therapeutic products in the areas of bone and pain products under the Voveran brand; transplantation immunology products under the Simulect, Certican, Sandimmun, Neoral, and Myfortic brands. It also offers neuroscience products under the Tegrital and Exelon brands. Novartis India Limited was incorporated in 1947 and is headquartered in Mumbai, India. Novartis India Limited operates as a subsidiary of Novartis AG. [Read more]
Financial Performance
In fiscal year 2025, Novartis India's revenue was 3.56 billion, an increase of 6.33% compared to the previous year's 3.35 billion. Earnings were 1.01 billion, an increase of 18.44%.
Financial StatementsNews
Novartis India stock surges 9% as Alkem Labs eyes ₹2,000 crore acquisition
Novartis India (BSE: ₹1,181.70) surged 8.95% in intraday trading at 3:02 PM, following reports by CNBC-TV18 indicating that Alkem Labs is in talks to acquire the company from its Swiss parent, Novarti...